Patients with cardiac rhythm disorders taking the fixed-dose combination of sofosbuvir and ledipasvir, or sofosbuvir in combination with daclatasvir, should be closely monitored if they are receiving concomitant amiodarone, especially during the first few weeks of concomitant treatment. Continuous monitoring for 48 hours is required for patients at high risk of bradyarrhythmia.
MHRA Drug Safety Update
Owing to the long half-life of amiodarone, patients who have discontinued the antiarrhythmic within the past few months and are to be initiated on either of the above antiviral combinations should be monitored.
- shortness of breath